Several cardiologists expressed surprise and disappointment at the results of the SYMPLICITY HTN-3 trial, but they cautioned against concluding that renal denervation has no place in the future treatment of resistant hypertension. Noting that the therapy has been shown effective in smaller studies and that several methods of denervation are currently under study, "this may just be the wrong approach and/or learning curve issues with rolling out the study to multiple operators," said SCAI fellow Dr. Cindy Grines. SCAI fellow Dr. Roxana Mehran called for those in the field to "step back and better understand this trial and the results before we shut out so many patients who may benefit from this type of therapy."

Related Summaries